However, different from the CLL experience, in which some resistance mechanisms (e.g., TP53 aberrations and some BCL2, NOTCH1, and BRAF mutations) have been described, in ALL, the genetic determinants of treatment response and failure have been poorly characterized (Gibson et al., 2022). The gene discussed is TP53; the disease is acute lymphoblastic leukemia.